U.S. regulatory panel backs approval for Merck C. difficile drug

June 9 (Reuters) - Merck & Co's experimental drug to

treat the most common cause of hospital-associated infectious

diarrhea warrants approval, an advisory panel to the U.S. Food

and Drug...

Read more